SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01482923

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations

"A treatment session especially for PLWHA to help them discuss and take action about their smoking may be useful."

NCT01482923 Tobacco Cessation HIV AIDS

2 Interventions

Name: Treatment as usual

Description: Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
Type: Behavioral
Group Labels: 1

Treatment As Usual (TAU)

Name: AIR (Aspirations, Inspiration, Respiration)

Description: Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
Type: Behavioral
Group Labels: 1

Aspiration, Inspiration Respiration, or AIR


Primary Outcomes

Description: The study will test whether the percentage of eligible and enrolled study participants who complete the assigned intervention is significantly different from a population of percentages centered at 45%, i.e., the "null population percentage," considered a percentage too low to be compatible with feasibility."

Measure: Feasibility of a motivational tobacco cessation intervention

Time: 2 years

Secondary Outcomes

Description: Assess potential factors influencing study participation by community organizations" and, as the description, "Descriptive statistics will be summarized by participating community organizations on each organization's "Implementation Factors" assessment, an agency study participation measure developed for this project. The measure assesses how many clients the agency has referred, what means were used to recruit, and what barriers to recruitment were encountered, and an open-ended question is provided for additional input."

Measure: Estimate the differences between the experimental intervention

Time: 2 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 M11Q

Inclusion Criteria: - Age 18 years or older as per self-report; - English speaking; - New York or New Jersey State resident; - HIV-positive serostatus direct referral from a CAB agency staff member, which verifies that the person is an HIV+ client, or by as verified by presentation of medical evidence (i.e.,confirmatory test result, ARV prescription, M11Q form, or lab results); - Self-report of smoking > or = to 20 cigarettes (> or = to one pack) within the prior 7 days; - To confirm smoking status, the carbon monoxide alveolar breath test must be > or = to 10 ppm; - To confirm cognitive functioning, score on the in-person BLESSED Exam must be < or = to 10; - Low income, defined by either: 1) Proof of Medicaid insurance, or 2) Self-report of income at 50% or below median income for New York State for New York State residents, or if a New Jersey resident, at or below 50% median income for New Jersey Exclusion Criteria: - Presence of current severe psychopathology that would limit study participation (e.g., unstable schizophrenia, bipolar disorder recent changes to medication noncompliance); - Currently receiving smoking cessation treatment elsewhere. --- M11Q ---



HPO Nodes